Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based GvHD Pr…

2024 ASCO® Annual Meeting Insights Hub

M. Al Malki

Selection and Sequencing of Chronic GVHD Therapy

Rush University Medical Center

S. Kosuri

The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibro…

Daniel Wolff

GVHD: Importance of Early Detection and Management

Ernst Holler

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Controversies and Recommendations for the Treatment of ALL and Lymph…

Indy Hematology Review

W. Stock

Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study

Zachariah DeFilipp

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults …

Insights from 2023 ASH Annual Meeting

M. Luskin

Chronic GVHD: A Case-Based Discussion

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

L. Perry

Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib i…

Insights from 2024 EHA Annual Meeting

J. Ribera

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

Current Approaches in the Frontline Treatment of Adult ALL

Louisville Hematology Highlights

N. Short